Please try another search
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Jeffrey S. Aronin | 55 | 2017 | Founder & Non-Executive Chairman |
Andreas Wicki | 65 | 2017 | Independent Director |
R. Mark Graf | 59 | 2020 | Independent Director |
Gary L. Sender | 61 | 2020 | Independent Director |
Jeffrey M. Dayno | 66 | 2017 | President, CEO & Director |
Linda M. Szyper | 57 | 2021 | Independent Director |
Juan A. Sabater | 58 | 2017 | Independent Director |
Jack Beck Nielsen | 59 | 2017 | Independent Director |
Antonio Jose Gracias | 53 | 2017 | Independent Director |
Peter Anastasiou | 54 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review